IDEAYA Biosciences, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 5, 2026, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026.”
IDEAYA Biosciences, Inc. — fact timeline
Source-grounded facts extracted from IDEAYA Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Susan L. Kelley, M.D. resigned as Director at IDEAYA Biosciences, Inc..
“Dr. Kelley will resign from the Board at the end of her current term, which will conclude immediately after the Annual Meeting.”
Joshua Bleharski was appointed as Chief Financial Officer at IDEAYA Biosciences, Inc..
“On February 10, 2025, the Board of Directors (the “Board”) of IDEAYA Biosciences, Inc. (the “Company”) appointed Joshua Bleharski, Ph.D. as Chief Financial Officer of the Company, effective early May 2025”
Jason Throne resigned as Chief Legal Officer and Secretary at IDEAYA Biosciences, Inc..
“On June 21, 2024, Jason Throne informed IDEAYA Biosciences, Inc. (the “Company”) of his voluntary resignation from his positions as Chief Legal Officer and Secretary of the Company.”
IDEAYA Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 7, 2024, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.”
IDEAYA Biosciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On February 20, 2024, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.